TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04982939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg IV d1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1, 40-60mg BID d1-14 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1, 40-60mg BID d1-14 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2 d1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin，130mg/m2 d1 Q3W
Study: NCT05014672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Oral tablets, 400mg per tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Oral tablets, 400mg per tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT04977284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS7R, Digitimer, UK
Description: Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
Study: NCT04932928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre
Description: Flash glucose monitoring + Education on lifestyle modification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose meter
Description: Self monitoring of blood glucose + Education on lifestyle modification
Study: NCT06610734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab combined with chemotherapy synchronous LDRT
Study: NCT05642585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Single oral
Study: NCT06610734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab
Description: Adebrelimab combined with chemotherapy synchronous LDRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy
Description: low dose radiotherapy
Study: NCT06610552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Powerly
Description: Powerly is a mental well-being mobile app, in which pregnant women can track their mood and level of stress, and receive personalized psychological modules to increase their mental health and well-being. By integrating evidence-based content and cognitive behavioral techniques with insights from pregnant and postpartum individuals and health professionals, Powerly offers a comprehensive psychological support including reappraisal, mental imagery, gratitude, mindfulness, self-efficacy and behavioral activation exercises.
Study: NCT06610188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic group
Description: products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
Study: NCT06609941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative nostril breathing
Description: Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Description: Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological therapy
Description: Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist.
Study: NCT05642585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral
Study: NCT06609759

Intervention type: DRUG
Intervention: Standard chemotherapy regimen
Description: In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.
Study: NCT06609707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: Tuning in to Kids is an evidence-based, emotion-focused, group parenting program designed to teach caregivers skills in recognizing, understanding, and managing their own and their children's emotions. The program includes six 90-minute, weekly, online group sessions and two optional 'booster' sessions to consolidate skills. Parents are taught five steps of emotion coaching and participate in exercises sequentially targeting each step. Intervention components include psychoeducation, emotion coaching demonstrations, role plays, group discussion, written resources, and home practice exercises. The program teaches parents skills in emotion coaching as a way of responding to their child's emotions. These skills help children to understand and regulate their emotions. As per the Tuning in to Kids manual, two trained, licensed health professionals will co-facilitate each group.
Study: NCT06611267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain without cream on
Description: Participants will be inflicted with pain without cream on.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain without cream on
Description: Participants will be inflicted with pain without cream on.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain with cream on
Description: Patients are inflicted with pain after getting a cream on, which has previously had pain-relieving effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain with cream on
Description: Patients are inflicted with pain after getting a cream on, which has previously had pain-relieving effects
Study: NCT04982835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M6-C Artificial Cervical Disc
Description: An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed so that the M6-C artificial cervical disc can be placed into the space where the damaged disc was removed. This procedure will be performed using x-ray technology (fluoroscopy) guide the surgeon in placement of the M6-C in between the cervical vertebrae. This process will be repeated to replace the second damaged disc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: One of four FDA-approved cervical plate systems will be used for the ACDF. An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed. Then, a piece of donor bone will be placed in the space where the damaged disc was removed and a metal plate will be screwed into the bones above and below the disc. This procedure will be performed using x-ray technology (fluoroscopy) to guide the surgeon in the placement of the cervical plate system. This process will be repeated to treat the other damaged disc.
Study: NCT05642585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral
Study: NCT06262789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return-to-work after cancer consultation
Description: The return-to-work after cancer consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation.
Study: NCT04907981

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel coronavirus infection
Description: Using eye examination to judge whether novel coronavirus is infected or not.
Study: NCT05055544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bearberry
Description: a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Study: NCT06379165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Nanocrystal Injection
Description: 30 mg (1 mL), once daily, by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL Placebo, once daily, by intravenous infusion
Study: NCT06035731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOCIO-AESTHETICS care
Description: SOCIO-AESTHETICS well being care performed by qualify person
Study: NCT05109780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My EMI, Emotional Well-being + self-applied online transdiagnostic treatment
Description: The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
Study: NCT06396234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe VLM and airway management
Description: Once the device is placed, following assessment, endotracheal intubation will be performed via the device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using video laryngoscope
Description: Endotracheal intubation (size 7.0 mm) using video laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaCo VLM and airway management
Description: Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
Study: NCT04528914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Description: The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
Study: NCT06728189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NKT Cells treatment
Description: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC738 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2;
Study: NCT06384508

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINE-VR
Description: The SHINE-VR takes place after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR, and is followed by the rest of the regular treatment. SHINE-VR consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINE-VR
Description: The SHINE-VR takes place after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR, and is followed by the rest of the regular treatment. SHINE-VR consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR.
Study: NCT06424444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap ophthalmic solution (0.25%)
Description: Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks
Study: NCT05416216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WELL
Description: The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
Study: NCT04941495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: 1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical proprioceptive training
Description: 1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.~7. The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted.
Study: NCT05007522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen/Indomethacin
Description: 2 mg tablet, 75 mg SR tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT06290596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Hemostatic drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Hemostatic drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT05297877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental AI Echo Machine
Description: Participants will go through the training programme using an AI machine for learning.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Echo Machine
Description: Participants will go through the training programme using a conventional machine for learning.
Study: NCT06073808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft
Description: Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Device
Description: Control device will be applied to non-experimental breast. Each patient will serve as their own control.
Study: NCT05378321

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-invasive diagnostic testing
Description: Non-invasive diagnostic testing consists of the use of the FibroScan device and the calculation of non-invasive blood-based scores for the diagnosis of NAFLD
Study: NCT05122728

Intervention type: OTHER
Intervention: Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment
Description: Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)

Intervention type: OTHER
Intervention: Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment
Description: Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)
Study: NCT06306209

Intervention type: OTHER
Intervention: Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management
Description: All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.